

Response to ASX Query

First Commercial Order for Ultranode battery anode with EV1

BRISBANE, AUSTRALIA, 18 October 2024: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary technologies provides the following response to an ASX Query received on 15 October 2024.

On 15 October 2024, the Company made an ASX announcement titled "*First Commercial Order for Ultranode battery anode*" (the **Announcement**). The Announcement (see Annexure A) referred to the Company's "First commercial order of Ultranode[™] from leading European EV manufacturer 'EV1'

The ASX has advised the Company that under Listing Rule 3.1 the counterparty referred to as EV1 must be identified.

The Company advises that:

- the counterparty, referred to as "EV1" in the Announcement, is Mercedes-Benz AG of Waiblingen, Germany, part of Mercedes-Benz Group AG (Mercedes-Benz)
- it has previously taken all efforts to protect the confidentiality of Mercedes Benz as "EV1" due to the stage of commercial relationship and the confidential nature of the work being undertaken.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

Attached: ASX Announcement, 15 October 2024

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo XTM, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind[™] provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not

ANTEOTECH LTD ACN 070 028 625

Unit 4, 26 Brandl St Brisbane Technology Park Eight Mile Plains QLD 4113 Australia





limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.



ANTEOTECH LTD ACN 070 028 625

Unit 4, 26 Brandl St Brisbane Technology Park Eight Mile Plains QLD 4113 Australia





<u>Annexure A:</u>

First Commercial Order for Ultranode battery anode

Leading EV manufacturer 'EV1' to commence evaluation of Ultranode[™] with 70% silicon

BRISBANE, AUSTRALIA, 15th October 2024: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary technologies, is pleased to announce that it has received the first commercial order for its proprietary Ultranode[™] battery anode technology containing 70% silicon.

Key Points

- First commercial order of Ultranode[™] from leading European EV manufacturer 'EV1'
- Ultranode[™] is a proprietary battery anode containing 70% silicon
- EV1 is seeking step change in silicon content for their next generation EV batteries
- EV1 evaluation of Ultranode will continue in parallel with the current development of an Anteo X[™] containing anode

David Radford, Managing Director & Chief Executive Officer of AnteoTech commented:

"We are pleased to expand our relationship with EV1 and support not only their current battery optimisation programme using Anteo X, but their future battery vision of increased silicon content anodes, which we believe only our Ultranode can offer them. The anode that is being purchased contains 70% silicon which is significantly higher than the anode currently being evaluated which has 10% silicon active material. This new commercial sale and evaluation will take place of the coming months and deepen our potential future engagement with this leading EV manufacturer."

First commercial order of Ultranode[™]

AnteoTech has received its first purchase order for the Ultranode[™] battery anode technology from EV1, a major European EV manufacturer. The purchase order is for approximately A\$40,000 as it relates to an initial quantity of Ultranode[™] for testing and evaluation over the coming months.

This initial order represents another milestone for AnteoTech and validates the ongoing development and key features of the AnteoTech proprietary 70% silicon Ultranode battery anode technology. EV1 will shortly commence an evaluation program where the performance enhancing characteristics of the Ultranode[™] will be assessed. The testing of Ultranode[™] will take place in parallel with EV1's ongoing evaluation of Anteo X^{™,} supporting both their current plans for battery optimisation and future goals of higher silicon battery anodes.

About Ultranode[™]

Ultranode[™] is AnteoTech's proprietary ultra-high silicon anode design currently containing 70% silicon. It is constructed using commercially available low-cost silicon as the active material (replacing graphite) and enabled by AnteoTech's technologies to offer a high performance and sustainable option for lithium-ion batteries.

This announcement has been authorised for release by the Company Secretary of AnteoTech Ltd.



ANTEOTECH LTD ACN 070 028 625

Unit 4, 26 Brandl St Brisbane Technology Park Eight Mile Plains QLD 4113 Australia